Neofect Secures Financial Safety Net... Performance Down on Subsidiary Sales View original image

Healthcare robotics specialist company Neofect announced its provisional results for last year through a disclosure on a "30% or more change in sales or profit structure." Its performance contracted due to factors such as the sale of inefficient subsidiaries and the cost of writing off non-performing assets. However, its financial soundness has improved significantly through a paid-in capital increase and the conversion of convertible bonds (CB) into equity. Neofect is confident that, with potential risk factors now removed, it will achieve more than fourfold growth this year compared to last year, based on its core business and new business lines.


Neofect stated on the 23rd that, on a consolidated basis, last year's sales were provisionally tallied at 16.0 billion won, down 24.1% from the previous year. During the same period, operating loss came to 3.5 billion won and net loss to 10.4 billion won, expanding by 46.47% and 608.16%, respectively, compared to a year earlier. This was due to the exclusion of all related annual operating revenue following the sale of its subsidiaries Knightsbridge and Cheonji Agency.


In particular, the company posted net profit of 6.8 billion won in the fourth quarter and returned to the black, but this was not enough to offset the existing cumulative net loss of 17.2 billion won in the first to third quarters, resulting in a full-year net loss of 10.4 billion won. The main cause of the net loss was non-cash financial costs such as valuation losses on CB derivatives. The company explained, "These losses are accounting profit-and-loss fluctuations that do not involve any cash outflow," adding, "We have ample buffer with respect to listing maintenance requirements, including sales and legal capital impairment tests."


The financial indicators improved markedly. On a consolidated basis, total assets last year were 79.6 billion won, up 10.02% from 72.4 billion won a year earlier. Over the same period, total equity increased 43.93% from 38.2 billion won to 55.1 billion won, while total liabilities decreased 28.06% from 34.1 billion won to 24.5 billion won. As a result, the debt ratio fell from 89.2% to 44.6%, down 44.6 percentage points, further strengthening financial stability. The company’s restructuring efforts, including the conversion of CB liabilities into equity last year, two paid-in capital increases, management efficiency measures, and asset revaluation, proved effective.


The management team that took office last August embarked on restructuring to correct the lax management of the previous leadership. It promoted: (1) the winding down of inefficient businesses, (2) the resolution of existing debt and the write-off of non-performing assets, and (3) the launch of new businesses to secure new growth engines. The company stressed, "The process of correcting past mistakes is also an important stepping stone for rebirth as a better company."


The company is also broadening its business direction. It plans to expand the scope of robotics applications beyond its existing focus on robot- and artificial intelligence (AI)-based rehabilitation devices. It also presented a strategy to advance AI and brain-computer interface (BCI)-based technologies into wearable robots and thereby diversify its customer base. In particular, on the back of turning its local subsidiaries in the United States and Germany to profitability, the company intends to sustain the improving trend in overseas business profitability.


In its new business, the company is accelerating the establishment of production facilities for its materials business, centered on the munitions chemistry sector. It plans to expand applications to pharmaceuticals, semiconductors, and secondary batteries, and thereby shift to a high value-added profit structure.



A Neofect official said, "It is significant that we have secured the financial capacity to pursue a full-scale growth strategy based on improved capital efficiency," adding, "Our overseas business has already turned profitable, and we have entered a phase of profit recovery and growth this year." The official continued, "As the main pipelines, including the expansion of our existing robotics business and our new materials business, go into full operation, we have set this year's sales target at a level four times higher than last year."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing